» Articles » PMID: 37592321

Efferocytosis of Viable Versus Heat-inactivated MSC Induces Human Monocytes to Distinct Immunosuppressive Phenotypes

Overview
Publisher Biomed Central
Date 2023 Aug 17
PMID 37592321
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Immunomodulation by mesenchymal stromal cells (MSCs) can occur through trophic factor mechanisms, however, intravenously infused MSCs are rapidly cleared from the body yet a potent immunotherapeutic response is still observed. Recent work suggests that monocytes contribute to the clearance of MSCs via efferocytosis, the body's natural mechanism for clearing dead and dying cells in a non-inflammatory manner. This begs the questions of how variations in MSC quality affect monocyte phenotype and if viable MSCs are even needed to elicit an immunosuppressive response.

Methods: Herein, we sought to dissect MSC's trophic mechanism from their efferocytic mechanisms and determine if the viability of MSCs prior to efferocytosis influences the resultant phenotype of monocytes. We cultured viable or heat-inactivated human umbilical cord MSCs with human peripheral blood mononuclear cells for 24 h and observed changes in monocyte surface marker expression and secretion profile. To isolate the effect of efferocytosis from MSC trophic factors, we used cell separation techniques to remove non-efferocytosed MSCs before challenging monocytes to suppress T-cells or respond to inflammatory stimuli. For all experiments, viable and heat-inactivated efferocytic-licensing of monocytes were compared to non-efferocytic-licensing control.

Results: We found that monocytes efferocytose viable and heat-inactivated MSCs equally, but only viable MSC-licensed monocytes suppress activated T-cells and suppression occurred even after depletion of residual MSCs. This provides direct evidence that monocytes that efferocytose viable MSCs are immunosuppressive. Further characterization of monocytes after efferocytosis showed that uptake of viable-but not heat inactivated-MSC resulted in monocytes secreting IL-10 and producing kynurenine. When monocytes were challenged with LPS, IL-2, and IFN-γ to simulate sepsis, monocytes that had efferocytosed viable MSC had higher levels of IDO while monocytes that efferocytosed heat inactivated-MSCs produced the lowest levels of TNF-α.

Conclusion: Collectively, these studies show that the quality of MSCs efferocytosed by monocytes polarize monocytes toward distinctive immunosuppressive phenotypes and highlights the need to tailor MSC therapies for specific indications.

Citing Articles

A protocol to isolate and characterize pure monocytes and generate monocyte-derived dendritic cells through FBS-Coated flasks.

Meskini M, Amanzadeh A, Salehi F, Bouzari S, Karimipoor M, Fuso A Sci Rep. 2024; 14(1):23956.

PMID: 39397067 PMC: 11471755. DOI: 10.1038/s41598-024-75376-3.


Mesenchymal stem cell therapy for liver transplantation: clinical progress and immunomodulatory properties.

Wen F, Yang G, Yu S, Liu H, Liao N, Liu Z Stem Cell Res Ther. 2024; 15(1):320.

PMID: 39334441 PMC: 11438256. DOI: 10.1186/s13287-024-03943-6.


Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution.

Sukka S, Ampomah P, Darville L, Ngai D, Wang X, Kuriakose G Nat Metab. 2024; 6(9):1736-1755.

PMID: 39242914 PMC: 11734744. DOI: 10.1038/s42255-024-01115-7.


Carbon monoxide-induced autophagy enhances human mesenchymal stromal cell function via paracrine actions in murine polymicrobial sepsis.

Hwang N, Ghanta S, Li Q, Lamattina A, Murzin E, Lederer J Mol Ther. 2024; 32(7):2232-2247.

PMID: 38734903 PMC: 11286814. DOI: 10.1016/j.ymthe.2024.05.018.


Reveal more mechanisms of precondition mesenchymal stem cells inhibiting inflammation.

Li Y, Chen Q, Linghu E World J Stem Cells. 2024; 16(4):459-461.

PMID: 38690518 PMC: 11056632. DOI: 10.4252/wjsc.v16.i4.459.

References
1.
Moll G, Ankrum J, Kamhieh-Milz J, Bieback K, Ringden O, Volk H . Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. Trends Mol Med. 2019; 25(2):149-163. DOI: 10.1016/j.molmed.2018.12.006. View

2.
Levy O, Kuai R, Siren E, Bhere D, Milton Y, Nissar N . Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020; 6(30):eaba6884. PMC: 7439491. DOI: 10.1126/sciadv.aba6884. View

3.
Boland L, Bitterlich L, Hogan A, Ankrum J, English K . Translating MSC Therapy in the Age of Obesity. Front Immunol. 2022; 13:943333. PMC: 9289617. DOI: 10.3389/fimmu.2022.943333. View

4.
Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q . Transplantation of ACE2 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020; 11(2):216-228. PMC: 7069465. DOI: 10.14336/AD.2020.0228. View

5.
Galipeau J . Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity. Stem Cells. 2021; 39(9):1145-1154. PMC: 8453730. DOI: 10.1002/stem.3380. View